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Purpose: Some long-term survivors after surgery for locally advanced non-small cell lung 2 
cancer (NSCLC) treated with induction chemoradiotherapy (trimodality treatment) develop 3 
chronic pulmonary aspergillosis (CPA). The aim of our study was to assess the 4 
characteristics and outcomes of CPA that develops after trimodality treatment. 5 
Methods: We retrospectively reviewed the data of 187 NSCLC patients who underwent 6 
trimodality treatment between 1999 and 2018. 7 
Results: Six male ever-smoker patients developed CPA. All 6 patients had undergone 8 
extended resection for NSCLC and had a history of either adjuvant chemotherapy (n=3) 9 
or radiation pneumonitis (n=4). Among the 4 patients with CPA localized in a single lung, 10 
3 patients were treated surgically (completion pneumonectomy or cavernostomy) and 1 11 
patient was treated with antifungal therapy alone. Both treatments led to the improved 12 
control of CPA. In contrast, patients with CPA in both lungs were not candidates for surgery, 13 
and died of CPA. The survival rates after trimodality treatment in the CPA group and the 14 
group without CPA were comparable (10-year survival rate, 50.0% vs. 57.6%, P=0.59). 15 
Conclusion: The early diagnosis of CPA localized in a single lung after NSCLC surgery 16 
is critical to improving control and survival in patients with CPA.  17 
 18 
Keywords: lung cancer; aspergillosis; surgery; radiation; chemotherapy19 




Chronic pulmonary aspergillosis (CPA), including simple aspergilloma and chronic 2 
cavitary pulmonary aspergillosis, sometimes develops in non-immunocompromised 3 
patients with prior or current lung disease [1]. Risk factors for CPA include chemotherapy 4 
[2], radiotherapy, thoracic surgery, and lung cancer [3-6], which are inevitable in patients 5 
who have undergone induction chemoradiotherapy followed by surgery for non-small cell 6 
lung cancer (NSCLC). Induction chemoradiotherapy followed by surgery has been shown 7 
to be a feasible therapeutic option for patients with locally advanced NSCLC [7], and this 8 
trimodality therapy for NSCLC has been shown to provide favorable long-term results [8], 9 
which have led to an increase in survivors of NSCLC. Thus, long-term survivors may 10 
develop CPA due to risk factors for CPA that are involved in trimodality therapy, despite 11 
the irradiated lung containing the NSCLC being resected at surgery. Furthermore, the risk 12 
of CPA may be increased by chronic obstructive lung disease, which is a common 13 
comorbidity of ever-smoker NSCLC patients as well as by prolonged corticosteroid 14 
therapy for radiation pneumonitis, which sometimes develops as a complication after 15 
chemoradiotherapy [1, 6, 9]. Although evidence has accumulated on the treatment of 16 
NSCLC by induction chemoradiotherapy followed by surgery [10], little information is 17 
available in relation to CPA after the trimodality therapy. The aim of our study was to 18 
assess the characteristics and outcomes of CPA after surgery for locally advanced NSCLC 19 




Trimodality therapy has been performed to treat NSCLC patients with mediastinal nodal 24 
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metastasis. It has also been selectively applied to the treatment of localized N3 or T3-1 
4N0-1M0 and, at the physician’s discretion, to patients with large or invasive tumors, such 2 
as bulky N1 tumors with chest wall invasion, or T4 involvement, as a means of achieving 3 
complete resection with a pathologic safety margin [11, 12]. This study was a retrospective 4 
review of cases of locally advanced NSCLC treated by induction chemoradiotherapy and 5 
surgery at Okayama University Hospital between January 1999 and December 2018. A 6 
total of 187 patients were included in this study. The inclusion criteria were an Eastern 7 
Cooperative Oncology Group performance status of 0 to 1 and adequate functional 8 
reserves of the major organs, as previously described [13]. Staging was performed 9 
according to the International Association for the Study of Lung Cancer TNM Staging 10 
System for NSCLC, eighth edition [14]. The study protocol (No. 1055) was approved by 11 
the Institutional Review Board of Okayama University Hospital. The requirement for 12 
patient consent was waived due to the retrospective nature of the study and the patients 13 
were informed of their right to opt out. 14 
 15 
Induction chemoradiotherapy followed by surgery 16 
The details of trimodality treatment as initial therapy targeting a primary NSCLC tumor 17 
have been described previously [8, 11, 15]. Briefly, most patients received cisplatin and 18 
docetaxel as induction chemotherapy, and some patients received alternative 19 
chemotherapy regimens. On the first day of chemotherapy, radiotherapy was initiated with 20 
a planned total radiation dose of 40–46 Gy. Dose escalation up to 60 Gy was allowed 21 
when tumors responded poorly. The surgical procedure after induction 22 
chemoradiotherapy was decided on the basis of the disease extent before the start of 23 
induction therapy. Although the preferred procedure was pulmonary lobectomy with 24 
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complete ipsilateral mediastinal and subcarinal nodal dissection, bilobectomy or 1 
pneumonectomy was performed to achieve complete resection when necessary. The 2 
patients received postoperative adjuvant therapy at the physician’s discretion. After the 3 
completion of trimodality treatment, the patients were followed up in accordance with our 4 
follow-up regimen [8]. 5 
 6 
Management of pulmonary aspergillosis 7 
The diagnosis of CPA during the follow-up period was confirmed on the basis of the clinical, 8 
laboratory, and radiographic findings, including testing for 1,3-beta-D-glucan and 9 
galactomannan antigen, cultures, bronchoscopy, chest X-ray, and chest computed 10 
tomography. After confirming the diagnosis of CPA, the patients were initially treated with 11 
antifungal agents. In accordance with the guidelines for the treatment of CPA published 12 
by the European Respiratory Society [1], after a careful risk assessment, surgery was 13 
considered for improved disease control in patients whose CPA was refractory to medical 14 
management. 15 
 16 
Statistical analysis 17 
All statistical analyses were performed using the GraphPad Prism 7.03 software program 18 
(San Diego, CA, USA). Overall survival was defined as the interval between the start of 19 
induction therapy and the date of death or the last follow-up examination. The survival 20 
rates were analyzed by the Kaplan–Meier method, and the log-rank test was used to 21 
compare the differences between groups. P values of <0.05 were considered to indicate 22 
statistical significance.  23 
 24 




Patient characteristics 2 
As shown in Table 1, six patients developed CPA after trimodality treatment for NSCLC. 3 
All 6 patients were male ever-smokers and had been histologically diagnosed with 4 
adenocarcinoma. All 6 patients underwent extended resection: combined resection in 4 5 
patients, N3 nodal dissection in one patient (Case 4), and bilobectomy in one patient 6 
(Case 6). The total number of resected lung segments was ≥4 in 5 patients. After surgery, 7 
3 patients received adjuvant chemotherapy, and 4 patients developed radiation 8 
pneumonitis. 9 
     Table 2 summarizes the details with regard to CPA. Five patients had cough and 10 
fever, and 3 patients had hemosputum. The intervals between the initial therapy for 11 
NSCLC and the diagnosis of CPA ranged from 1.3 years to 9.9 years. Testing for 1,3-beta-12 
D-glucan and galactomannan antigen was positive in two patients each. Aspergillus 13 
fumigatus was detected in 4 patients, and Pseudomonas aeruginosa was detected in the 14 
sputum culture of one patient (Case 2). It is noteworthy that in each patient computed 15 
tomography showed consolidation in the single remaining lung or both lungs as well as a 16 
cavity at the resection site. A fungus ball was demonstrated in 4 patients, and a 17 
bronchopleural fistula was diagnosed in the other 2 patients, who were diagnosed with 18 
empyema (Case 1 and 2). Cavernostomy with fenestration was initially performed in the 19 
2 empyema cases, and one patient (Case 1) subsequently underwent completion 20 
pneumonectomy. Completion pneumonectomy was performed as the initial surgery in the 21 
patient (Case 3) who had no comorbidities (Fig. 1). A prompt diagnosis of CPA was 22 
achieved in Case 4 during close follow-up of glucocorticoid tapering for radiation 23 
pneumonitis, and CPA was subsequently successful controlled with antifungal agents (Fig. 24 
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2). The 2 patients with bilateral CPA lesions (Fig. 3) were not considered to be candidates 1 
for surgery and died of CPA. The 4 patients with a unilateral CPA lesion are still alive. The 2 
overall survival rate of the CPA group was similar to that of the group without CPA after 3 
trimodality treatment for NSCLC (P=0.59). It is noteworthy that no cancer recurrence or 4 
death was observed among the NSCLC patients who developed CPA, which is an 5 




In this study we elucidated the characteristics of CPA that developed in patients who had 10 
undergone surgery for locally advanced NSCLC after induction chemoradiotherapy and 11 
the outcomes of patients with CPA after trimodality treatment. All patients who 12 
subsequently developed CPA had undergone extended resection for NSCLC and had a 13 
history of either adjuvant chemotherapy or radiation pneumonitis. CPA developed at the 14 
resection site of all 6 patients, and the 4 patients whose CPA was localized in a remaining 15 
lobe in a single lung at the time of the diagnosis were considered to be candidates for 16 
surgery, which resulted in improved CPA control and long-term survival. To the best of our 17 
knowledge, this is the first report describing CPA after trimodality treatment. 18 
     Trimodality treatment for NSCLC, which consists of chemotherapy, radiotherapy, 19 
and surgery, may itself be a risk factor for CPA [2-6]. Adjuvant chemotherapy may further 20 
increase the risk of developing CPA [2], and radiation pneumonitis may contribute to the 21 
development of a destroyed lung, which is susceptible to aspergillus infection. In addition, 22 
extended lung resection may lead to the compensatory overexpansion of the remaining 23 
lobes, especially in the emphysematous lungs of ever-smokers, as was observed in this 24 
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study, and contribute to cavity formation in the pulmonary parenchyma. Furthermore, 1 
treatment of lung infections and second primary cancer may prolong patient survival after 2 
trimodality treatment for NSCLC [16]. In view of these factors, physicians should be aware 3 
of CPA as a possible late complication after trimodality treatment for NSCLC. 4 
     The diagnosis of CPA requires a consistent appearance on computed tomography, 5 
such as a cavity and fungus ball, which are direct evidence of Aspergillus infection, or 6 
evidence of an immunological response to Aspergillus species and the exclusion of other 7 
diagnoses [1]. No Aspergillus species were detected in 2 of our patients (Cases 2 and 4). 8 
Because an antagonistic relationship has been shown to exist between Aspergillus 9 
fumigatus and Pseudomonas aeruginosa [17], in Case 2, in which a fungal infection was 10 
histologically diagnosed based on the examination of the surgical specimen, the 11 
pseudomonal infection may have resulted in a false-negative Aspergillus culture. In Case 12 
4, the presence of a fungus ball and a positive galactomannan antigen test contributed to 13 
the early diagnosis of CPA. An early diagnosis of CPA is required for effective treatment 14 
to prevent the spread of CPA from one lung to the contralateral lung. 15 
     The localization of CPA in a single lung after NSCLC surgery at the time of the 16 
diagnosis may be a key to the improved control of CPA after trimodality treatment for 17 
NSCLC. Three patients with CPA in a single lung after NSCLC surgery underwent 18 
successful surgery, including completion pneumonectomy. Another patient, whose CPA 19 
remains well controlled with antifungal agents, would still be a candidate for surgery, even 20 
if their condition deteriorated. Because pneumonectomy has been shown to provide 21 
favorable results as a treatment for complex aspergilloma [18], completion 22 
pneumonectomy may be a therapeutic option for operable CPA patients after trimodality 23 
treatment for NSCLC. Survivors of NSCLC after trimodality treatment who have risk 24 
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factors for CPA might benefit from prophylactic antifungal therapy, which is routinely 1 
administered to lung transplant recipients [19]. The further accumulation of cases of CPA 2 
after trimodality treatment will be necessary for a more detailed evaluation. 3 
     In conclusion, careful follow-up is necessary to detect CPA as a late complication 4 
after surgery for locally advanced NSCLC treated with induction chemoradiotherapy, 5 
especially in ever-smoker patients who have undergone extended resection and have a 6 
history of either adjuvant chemotherapy or radiation pneumonitis. The early detection and 7 
diagnosis of CPA localized in a single lung after NSCLC surgery is critical to improving the 8 
control of CPA with antifungal agents and surgery as well as long-term survival after 9 
trimodality treatment. 10 
 11 
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Figure legends  1 
Fig. 1 Representative diagnostic images of surgical cases of chronic pulmonary 2 
aspergillosis in a single lung after trimodality treatment (Case 3). A preoperative chest X-3 
ray film (a) and computed tomography scan (b) showed a cavity and fungus ball in the 4 
remaining left upper lobe. A postoperative chest X-ray film showed fluid accumulation in 5 
the left post-pneumonectomy space (c).  6 










Sugimoto et al. 
 
 15 
Fig. 2 A case of successful medical management of chronic pulmonary aspergillosis in a 1 
single lung after trimodality treatment (Case 4). A chest X-ray film (a) and computed 2 
tomography scan (b) revealed a cavity and fungus ball (arrow) in the left lower lobe 3 
remnant. A chest X-ray film (c) and computed tomography scan (d) after antifungal therapy 4 
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Fig. 3 Representative diagnostic images of chronic pulmonary aspergillosis in both lungs 1 
(Case 5). A chest X-ray film (a) and computed tomography scans showed a cavity with a 2 
thickened wall in the remaining lower lobe of the left lung (b) and consolidation in both 3 
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Fig. 4 Survival of patients who developed chronic pulmonary aspergillosis (CPA) and 1 
those who did not develop CPA after trimodality treatment for locally advanced non-small 2 
cell lung cancer. The survival rates of the CPA and non-CPA groups were comparable (10-3 
year survival rate, 50.0% vs. 57.6%, respectively, P=0.59).  4 
 5 
